- Home
- ACRS vs TAYD Comparison
ACRS vs TAYD Comparison
Compare ACRS & TAYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- TAYD
- Stock Information
- Founded
- ACRS 2012
- TAYD 1955
- Country
- ACRS United States
- TAYD United States
- Employees
- ACRS N/A
- TAYD N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- TAYD Industrial Machinery/Components
- Sector
- ACRS Health Care
- TAYD Industrials
- Exchange
- ACRS Nasdaq
- TAYD Nasdaq
- Market Cap
- ACRS 132.0M
- TAYD 150.7M
- IPO Year
- ACRS 2015
- TAYD N/A
- Fundamental
- Price
- ACRS $2.72
- TAYD $41.13
- Analyst Decision
- ACRS Strong Buy
- TAYD
- Analyst Count
- ACRS 5
- TAYD 0
- Target Price
- ACRS $8.75
- TAYD N/A
- AVG Volume (30 Days)
- ACRS 1.1M
- TAYD 21.6K
- Earning Date
- ACRS 11-06-2024
- TAYD 01-08-2025
- Dividend Yield
- ACRS N/A
- TAYD N/A
- EPS Growth
- ACRS N/A
- TAYD 44.55
- EPS
- ACRS N/A
- TAYD 2.90
- Revenue
- ACRS $27,079,000.00
- TAYD $46,277,035.00
- Revenue This Year
- ACRS N/A
- TAYD N/A
- Revenue Next Year
- ACRS N/A
- TAYD N/A
- P/E Ratio
- ACRS N/A
- TAYD $14.19
- Revenue Growth
- ACRS 26.35
- TAYD 12.78
- 52 Week Low
- ACRS $0.86
- TAYD $21.99
- 52 Week High
- ACRS $5.17
- TAYD $64.50
- Technical
- Relative Strength Index (RSI)
- ACRS 41.17
- TAYD 37.67
- Support Level
- ACRS $2.91
- TAYD $40.73
- Resistance Level
- ACRS $3.29
- TAYD $46.51
- Average True Range (ATR)
- ACRS 0.29
- TAYD 2.19
- MACD
- ACRS -0.18
- TAYD -0.44
- Stochastic Oscillator
- ACRS 0.75
- TAYD 4.22
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About TAYD Taylor Devices Inc.
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.